Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic is well positioned by vidofludimus calcium’s differentiated profile: a once-daily oral DHODH inhibitor with Nurr1 activation, supported by Phase 2 evidence showing MRI lesion reduction, durable disability outcomes, and no meaningful hepatotoxicity or infection signal across 3500+ patients. The ENSURE-1 and ENSURE-2 Phase 3 RMS trials enrolled 1,121 and 1,100 patients, respectively, and had not met futility criteria, while follow-on PPMS development could extend the opportunity into a large, underserved progressive MS market. Financially, a February 2026 PIPE added about $200MM gross and management expects warrant proceeds to extend runway into late 2028, while patent protection potentially extends into 2041 and beyond, strengthening the long-term commercial case.

Immunic is fundamentally challenged by a high-risk, clinical-stage profile in which value depends on successful Phase 3 outcomes for IMU-838 and other pipeline assets, yet the cited bear cases still assign only 15% and 5% probabilities to key downside scenarios because efficacy or safety disappointments could sharply impair adoption. Even with 3500+ patients dosed and no clear increase in hepatotoxicity or serious infections to date, the company remains exposed to regulatory delay, manufacturing execution risk, and the possibility that safety signals or only modest efficacy limit commercial uptake in crowded markets with approved and generic DMTs. The excerpt also highlights anticipated additional funding needs over a 3.5-4 year trial timeline and potential dilution from warrants, making the stock vulnerable despite any isolated clinical progress.